A Promising Depression Drug Misses Its Main Goal
An experimental depression drug being developed by Contineum Therapeutics in collaboration with Johnson & Johnson has failed to meet the primary efficacy goal of a Phase 2 clinical trial in adults with major depressive disorder.
The drug, known as JNJ 5120 or PIPE 307, was being investigated as a potential new approach to treating depression. The MOONLIGHT 1 trial assessed whether the treatment could produce a meaningful improvement in depressive symptoms compared with placebo.
What Did the Clinical Trial Test?
The Phase 2 MOONLIGHT 1 study was designed as a randomized, double blind, multicenter and placebo controlled proof of concept trial.
Researchers evaluated changes in depression symptoms using the Montgomery Åsberg Depression Rating Scale, commonly known as MADRS. The primary endpoint focused on the change from baseline at Day 5 compared with placebo.
However, JNJ 5120 did not achieve the required improvement on this primary efficacy measure.
Why Was This Drug Considered Different?
One of the key features of JNJ 5120 was its mechanism of action.
The experimental treatment targets the M1 receptor in the brain. Unlike many conventional antidepressants that can take several weeks to produce noticeable benefits, the drug was being investigated for its potential to act much more quickly, with researchers looking for improvements within days.
A faster acting antidepressant could potentially address an important unmet need, particularly for patients who experience severe symptoms or do not respond adequately to existing treatments.
Safety Results Were More Encouraging
Although the drug failed to meet its primary efficacy endpoint, the safety findings from the study were more positive.
Contineum reported that JNJ 5120 was well tolerated and that no new safety signals were identified during the trial. This means the setback was primarily related to demonstrating the required treatment benefit rather than the emergence of a new safety concern in the study.
Safety and efficacy are evaluated separately in clinical development, so an acceptable safety profile alone is not sufficient to establish that an experimental medicine works.
Johnson & Johnson Will Review the Broader Data
The failed primary endpoint does not necessarily mean that every question surrounding the drug has been answered.
Johnson & Johnson is continuing to evaluate the broader MOONLIGHT 1 dataset, including prespecified exploratory endpoints. The company will assess the overall clinical relevance of the findings before determining the next steps for JNJ 5120.
This process is important because clinical trials generate multiple layers of information beyond the primary endpoint. However, exploratory findings should be interpreted cautiously and cannot replace a successful primary efficacy outcome.
Another Setback for the Same Compound
The latest result also follows an earlier clinical setback involving PIPE 307.
In 2025, a study investigating the same compound in patients with multiple sclerosis failed to demonstrate the expected benefit. The new depression trial therefore represents another challenge for the development program.
For pharmaceutical research, such outcomes highlight the uncertainty involved in translating promising biological mechanisms into effective treatments for patients.
Why New Depression Treatments Still Matter
Major depressive disorder remains a significant global health challenge, and many patients do not achieve adequate relief with currently available treatments.
This creates continued interest in therapies that could work through different biological pathways, act more rapidly, or help patients who have not responded sufficiently to existing options.
Recent research into other rapid acting approaches also shows how actively the field is exploring alternatives to traditional antidepressant strategies.
What Happens Next?
The immediate focus will be on the complete MOONLIGHT 1 dataset and the assessment of its exploratory findings.
For now, JNJ 5120 remains an investigational medicine and cannot be considered an established treatment for major depressive disorder. The trial result reinforces why promising laboratory mechanisms must ultimately demonstrate meaningful clinical benefit through well controlled human studies.
The Bigger Lesson for Depression Research
A failed Phase 2 trial is a setback, but it is also part of the scientific process.
Depression is biologically complex, and treatments that appear promising in earlier research do not always translate into meaningful improvements for patients. Clinical trials help distinguish biological promise from demonstrated therapeutic benefit.
The latest results from JNJ 5120 underline the importance of rigorous evidence, careful interpretation of clinical endpoints and continued investment in new approaches to mental health treatment.
